头颈癌患者与高额医疗费用:一项基于人群的研究
这项基于加拿大安大略省行政数据的回顾性队列研究纳入2007年1月至2020年10月诊断的13795例头颈癌成人患者,25%在诊断后第一年产生高额医疗费用(>第75百分位)。癌症分期是最强预测因素,相比I期,II期、III期、IV期患者高费用比值比分别为3.14、6.08、8.94;接受多种治疗模式也与高费用相关。作者认为优先开展筛查、早期诊断和有效的治疗降阶梯策略可能减少部分高额费用。
要点
- 13795例头颈癌患者中25%在诊断后第一年产生高额医疗费用。
- 癌症分期是最强预测因素,IV期患者高费用比值比为8.94。
- 接受多种治疗模式也与高额医疗费用相关。
核心结论
- 更晚的疾病分期和接受多种治疗模式是头颈癌患者高额医疗费用的最强预测因素。
研究设计与样本
- 基于人群的回顾性队列研究,使用加拿大安大略省临床评估科学研究所的行政数据,纳入2007年1月至2020年10月诊断的13795例头颈癌成人患者(平均年龄63.2岁,标准差11.7,女性3452例占25.0%),随访至诊断后1.5年或死亡或2021年10月31日。
主要发现
- 3448例(25%)患者在诊断后第一年产生高额医疗费用(>第75百分位)。
- 相比I期患者,II期患者高额医疗费用的比值比为3.14(95%CI 2.56-3.84),III期为6.08(95%CI 4.99-7.41),IV期为8.94(95%CI 7.43-10.80)。
- 接受多种治疗模式与高额医疗费用的更高比值比相关。
临床怎么用
- 作者认为,优先开展筛查项目的研究与实施、更早的癌症诊断以及有效的治疗降阶梯策略,可能减少相当一部分高额费用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The care for a small subset of patients is responsible for a disproportionately large share of health care expenditures. Head and neck cancer is associated with significant health care costs due to complex treatment regimens and long-term sequelae. Given this high baseline cost, identifying patients with high care costs within a population with cancer might help inform interventions to optimize resource allocation. OBJECTIVE: To characterize patients with head and neck cancer with the highest health care costs during the first year after diagnosis. DESIGN, SETTING, AND PARTICIPANTS: A population-based, retrospective cohort study was conducted using administrative data from the Institute for Clinical and Evaluative Sciences in Ontario, Canada, and included adults diagnosed with head and neck cancer between January 2007 and October 2020 (identified from the provincial cancer registry) with a full 1.5-year follow-up from the date of diagnosis to the date of death or October 31, 2021. The total 1-year health care costs were estimated using a patient-level algorithm and were collected in 2020 Canadian dollar values. The main analyses were performed in April 2023 and a sensitivity analysis was performed in April 2025. MAIN OUTCOMES AND MEASURES: High health care costs (>75th percentile) during the first year after a head and neck cancer diagnosis. Predictors of high health care costs were identified using a multivariable logistic regression model. RESULTS: The cohort included 13 795 patients (mean age, 63.2 [SD, 11.7] years and 3452 [25.0%] were female), 3448 (25%) of whom had high health care costs. Cancer stage was the strongest predictor of high health care costs. Compared with patients with stage I cancer, those with stage II cancer had 2-fold greater odds for high health care costs (odds ratio [OR], 3.14 [95% CI, 2.56-3.84]), those with stage III cancer had 5-fold greater odds for high health care costs (OR, 6.08 [95% CI, 4.99-7.41]), and those with stage IV cancer had 8-fold greater odds for high health care costs (OR, 8.94 [95% CI, 7.43-10.80]). Receiving multiple treatment modalities also was associated with greater odds for high-cost care. CONCLUSIONS AND RELEVANCE: This cohort study found that more advanced disease stage and receiving multiple treatment modalities were the strongest predictors of high-cost care among patients diagnosed with head and neck cancer. Prioritizing research and implementation of screening programs, earlier cancer diagnoses, and effective treatment deescalation strategies might mitigate a significant portion of these high costs.
引用
- Villemure-Poliquin N, Fu R, Li Q, et al. Patients With Head and Neck Cancer and High Health Care Costs: A Population-Based Study. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40674044. doi:10.1001/jamaoto.2025.1976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。